ArticleBMC cancer2026
Risk signals and clinical characteristics of serious adverse events of neutropenia associated with pembrolizumab: a FAERS database study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to characterize the risk signals and clinical features of pembrolizumab-associated neutropenia reported as serious adverse events (SAEs) in the US FDA Adverse Event Reporting System (FAERS), and the association between concomitant chemotherapy and time-to-onset.
methodsIn this retrospective pharmacovigilance study, SAE reports from FAERS (2021Q1–2024Q2) with pembrolizumab designated as the primary suspect drug were analyzed. Among 14,747 pembrolizumab-associated SAE reports, 856 with the Preferred Term “neutropenia” were identified and characterized. Clinical characteristics were summarized, and subgroup analyses explored associations between concomitant chemotherapy and TTO, as well as between sex and the reporting odds ratio (ROR). A supplementary analysis of febrile neutropenia (FN) cases was conducted to assess clinical severity.
resultsAmong 14,747 SAEs, 856 were neutropenia cases, for which a strong signal of disproportional reporting was detected (ROR = 5.23, 95% CI: 4.88–5.60). Median patient age was 61.0 years, and the reported mortality rate was 19.4%. A higher ROR was observed in females (7.06) than males (4.42), a difference likely influenced by the underlying distribution of cancer types and the 9.8% missing data for sex, rather than indicating an intrinsic sex-related risk. The overall median TTO was 19.0 days, with the concomitant chemotherapy group (N = 268) showing a shorter median TTO (14.5 days) than the non-chemotherapy group (N = 55, 39.0 days; p = 0.0006). Among 311 FN cases, 86.5% (269/311) occurred in the concomitant chemotherapy group.
conclusionPembrolizumab-associated neutropenia represents a notable safety signal in FAERS. The observed early-onset pattern, particularly in the context of concomitant chemotherapy, provides real-world evidence characterizing the clinical features of this adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.